Heterogeneity of TMPRSS2 gene rearrangements in multifocal prostate adenocarcinoma: molecular evidence for an independent group of diseases - PubMed (original) (raw)
Heterogeneity of TMPRSS2 gene rearrangements in multifocal prostate adenocarcinoma: molecular evidence for an independent group of diseases
Rohit Mehra et al. Cancer Res. 2007.
Abstract
Recurrent gene fusions between the androgen-regulated gene TMPRSS2 and the ETS family transcription factors ERG, ETV1, and ETV4 have been identified in the majority of prostate adenocarcinomas (PCA). PCA is often multifocal with histologic heterogeneity of different tumor foci. As TMPRSS2 is a common 5' partner of ETS gene fusions, we monitored TMPRSS2 rearrangement by fluorescence in situ hybridization (FISH) to study the origin and molecular basis of multifocal PCA heterogeneity. TMPRSS2 rearrangement was evaluated by FISH on a tissue microarray representing 93 multifocal PCAs from 43 radical prostatectomy resections. Overall, 70% (30 of 43) of the cases showed TMPRSS2 rearrangement, including 63% through deletion (loss of the 3' TMPRSS2 signal), 27% through translocation (split of 5' and 3' TMPRSS2 signals), and 10% through both mechanisms in different tumor foci. Of the 30 TMPRSS2 rearranged cases, 30% showed concordance in all tumor foci, whereas 70% were discordant in at least one focus. In TMPRSS2 rearranged cases, the largest (index) tumor was rearranged 83% of the time. Pathologic stage, size, or Gleason grade of the multifocal PCA did not correlate with overall TMPRSS2 rearrangement. Our results suggest that multifocal PCA is a heterogeneous group of diseases arising from multiple, independent clonal expansions. Understanding this molecular heterogeneity is critical to the future development and utility of diagnostic and prognostic PCA biomarkers.
Similar articles
- Detection of TMPRSS2 gene deletions and translocations in carcinoma, intraepithelial neoplasia, and normal epithelium of the prostate by direct fluorescence in situ hybridization.
Zhang S, Pavlovitz B, Tull J, Wang Y, Deng FM, Fuller C. Zhang S, et al. Diagn Mol Pathol. 2010 Sep;19(3):151-6. doi: 10.1097/PDM.0b013e3181bb216a. Diagn Mol Pathol. 2010. PMID: 20736744 - [Frequency and transcript variant analysis of gene fusions between TMPRSS2 and ETS transcription factor genes in prostate cancer].
Dai MJ, Chen LL, Zheng YB, Chen W, Tao ZH, Weng ZL, Wu XL, Li CD, Chen ZG, Chen XD, Shi SB. Dai MJ, et al. Zhonghua Yi Xue Za Zhi. 2008 Mar 11;88(10):669-73. Zhonghua Yi Xue Za Zhi. 2008. PMID: 18642766 Chinese. - Molecular genetic analyses of the TMPRSS2-ERG and TMPRSS2-ETV1 gene fusions in 50 cases of prostate cancer.
Winnes M, Lissbrant E, Damber JE, Stenman G. Winnes M, et al. Oncol Rep. 2007 May;17(5):1033-6. Oncol Rep. 2007. PMID: 17390040 - ETS gene fusions in prostate cancer: from discovery to daily clinical practice.
Tomlins SA, Bjartell A, Chinnaiyan AM, Jenster G, Nam RK, Rubin MA, Schalken JA. Tomlins SA, et al. Eur Urol. 2009 Aug;56(2):275-86. doi: 10.1016/j.eururo.2009.04.036. Epub 2009 Apr 24. Eur Urol. 2009. PMID: 19409690 Review.
Cited by
- The genomic landscape of prostate cancer.
Baca SC, Garraway LA. Baca SC, et al. Front Endocrinol (Lausanne). 2012 May 16;3:69. doi: 10.3389/fendo.2012.00069. eCollection 2012. Front Endocrinol (Lausanne). 2012. PMID: 22649426 Free PMC article. - Integrin-linked kinase as a target for ERG-mediated invasive properties in prostate cancer models.
Becker-Santos DD, Guo Y, Ghaffari M, Vickers ED, Lehman M, Altamirano-Dimas M, Oloumi A, Furukawa J, Sharma M, Wang Y, Dedhar S, Cox ME. Becker-Santos DD, et al. Carcinogenesis. 2012 Dec;33(12):2558-67. doi: 10.1093/carcin/bgs285. Epub 2012 Oct 1. Carcinogenesis. 2012. PMID: 23027626 Free PMC article. - Leveraging artificial intelligence to predict ERG gene fusion status in prostate cancer.
Dadhania V, Gonzalez D, Yousif M, Cheng J, Morgan TM, Spratt DE, Reichert ZR, Mannan R, Wang X, Chinnaiyan A, Cao X, Dhanasekaran SM, Chinnaiyan AM, Pantanowitz L, Mehra R. Dadhania V, et al. BMC Cancer. 2022 May 5;22(1):494. doi: 10.1186/s12885-022-09559-4. BMC Cancer. 2022. PMID: 35513774 Free PMC article. - Immunohistochemistry for ERG expression as a surrogate for TMPRSS2-ERG fusion detection in prostatic adenocarcinomas.
Chaux A, Albadine R, Toubaji A, Hicks J, Meeker A, Platz EA, De Marzo AM, Netto GJ. Chaux A, et al. Am J Surg Pathol. 2011 Jul;35(7):1014-20. doi: 10.1097/PAS.0b013e31821e8761. Am J Surg Pathol. 2011. PMID: 21677539 Free PMC article. - Circulating tumor cells in prostate cancer.
Hu B, Rochefort H, Goldkorn A. Hu B, et al. Cancers (Basel). 2013 Dec 4;5(4):1676-90. doi: 10.3390/cancers5041676. Cancers (Basel). 2013. PMID: 24305656 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials